Kerur B, Litman HJ, Stern JB, Weber S, Lightdale JR, Rufo PA, Bousvaros A. Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol 2017; 23(18): 3322-3329 [PMID: 28566893 DOI: 10.3748/wjg.v23.i18.3322]
Corresponding Author of This Article
Basavaraj Kerur, MD, Pediatric Gastroenterology, Hasbro Children’s Hospital, Providence, MPH 134, 593 Eddy St, RI 02903, United States. kerurbas@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 14, 2017; 23(18): 3322-3329 Published online May 14, 2017. doi: 10.3748/wjg.v23.i18.3322
Table 1 Descriptive information regarding the dataset (n = 99)
Characteristic
n (%)
Gender
Male
47 (47)
Female
52 (53)
Ulcerative colitis (UC) duration - scope
New onset
1 (1)
< 1 yr
16 (16)
1-3 yr
30 (30)
3-5 yr
16 (16)
> 5 yr
36 (36)
Indication for procedure
Suspicion of UC
1 (1)
Active symptoms
61 (62)
Consideration of Medication change
10 (10)
Assessment of Medication efficacy
13 (14)
Cancer screening
14 (14)
Paris classification
E1 Proctitis
1 (1)
E2 Left-sided
20 (20)
E3 Extensive
5 (5)
E4 Pancolitis
73 (74)
Medications at time of colonoscopy
5-aminosalicylic acid (5 ASA)
67 (68)
Steroids
30 (30)
Mercaptopurine/methotrexate
33 (33)
Infliximab/adalimumab
12 (12)
Antibiotics
10 (10)
Five ASA Enema
5 (5)
Hydrocortisone Enema
10 (10)
Methotrexate
1 (1)
Tacrolimus
3 (3)
VSL 3 probiotic
10 (10)
Table 2 Inter-observer agreement in grading rectal disease severity (Mayo scores) between reviewers
Reviewer AB
Reviewer PR
0
1
2
3
Unknown
Total
0
22
4
1
0
0
27
1
1
22
12
1
0
36
2
0
2
8
4
0
14
3
0
0
1
3
0
4
Unknown
0
0
0
0
18
18
Total
23
28
22
8
18
99
Table 3 Inter-observer agreement in grading sigmoid disease severity (Mayo score) between reviewers
Reviewer AB
Reviewer PR
0
1
2
3
Unknown
Total
0
22
5
0
0
0
27
1
2
22
12
4
0
40
2
0
3
9
7
0
19
3
0
0
5
3
0
8
Unknown
0
0
0
0
5
5
Total
24
30
26
14
5
99
Table 4 Pediatric ulcerative colitis activity index data by component
Characteristic
mean ± SD or n (%)
Age at time of colonoscopy (yr)
15.7 (4.1)
Days between colonoscopy and PUCAI score
14.8 (10.6)
Method of PUCAI collection
Prospectively entered at time of clinic visit
27 (27)
Calculated from medical record
72 (73)
Abdominal pain
No pain
52 (53)
Present but ignored
36 (36)
Cannot be ignored
11 (11)
Rectal bleeding
None
49 (49)
Small amount, < 50%
20 (20)
Small amount, most
27 (27)
Large amount
3 (3)
Consistency
Formed
57 (58)
Partially formed
35 (35)
Completely unformed
7 (7)
Number of stools
0-2
61 (62)
3-5
21 (21)
6-8
11 (11)
> 8
6 (6)
Nocturnal stools
18 (18)
Activity limitation
No limitation
62 (63)
Occasional limitation
29 (29)
Severe restriction
8 (8)
Overall activity
Remission, 0-9
33 (33)
Mild, 10-34
39 (39)
Moderate, 35-64
23 (23)
Severe, > 64
4 (4)
Citation: Kerur B, Litman HJ, Stern JB, Weber S, Lightdale JR, Rufo PA, Bousvaros A. Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol 2017; 23(18): 3322-3329